Description
What Adrisome is?
Adrisome is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel and platinum-based chemotherapy regimens. Refractory disease is defined as a disease that has progressed while on treatment or within 6 months of completing treatment.
Adrisome is indicated as monotherapy for the treatment of metastatic breast cancer, where there is an increased cardiac risk.
Adrisome is also indicated for the treatment of AIDS-related Kaposi’s Sarcoma in patients with extensive mucocutaneous or visceral disease that has progressed on prior combination therapy (consisting of two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin or another anthracycline) or in patients who are intolerant to such therapy.
What Doxorubicin is?
Doxorubicin is a chemotherapy medication used to treat cancer. This includes breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphocytic leukemia. It is often used together with other chemotherapy agents.
